News and updates from IPOX®, including media mentions, interviews, research and press releases.
IPOX® CEO Josef Schuster was interviewed by Bloomberg to discuss Venture Global's aftermarket performance following its recent IPO. Schuster provided insights into the challenging market conditions faced by Venture Global, emphasizing its notably poor stock performance compared to other major energy IPOs in recent decades.
IPOX® CEO Josef Schuster commented in a recent Reuters article, "Karman Holdings valued at nearly $4 billion as shares jump in NYSE debut", offering expert analysis on Karman Holdings' successful IPO and the broader market trends favoring defense and space companies.
IPOX® CEO Josef Schuster was quoted in a recent Reuters article, "Cybersecurity firm SailPoint sets sights on $12.6 billion valuation in US IPO", providing expert insight into SailPoint's IPO and the broader implications for the technology IPO market.
IPOX® Research Analyst Lukas Muehlbauer offered his perspective on the market debut of Maze Therapeutics (MAZE.O), a drug developer focused on chronic kidney diseases. Maze's shares saw a modest 1% increase on its Nasdaq debut, valuing the company at $690.37 million. The company’s debut follows an upsized IPO that raised $140 million.
IPOX® Research Analyst Lukas Muehlbauer offered his expert perspective on the market debut of Metsera, a GLP-1 weight-loss drug developer that achieved a $2.7 billion valuation following a 42% surge in its Nasdaq IPO. Metsera's strong performance underscores the robust investor appetite within the innovative obesity therapeutics sector.
IPOX® CEO Josef Schuster told Reuters that Venture Global's IPO "low float" presents a "significant risk," underscoring a challenging environment for energy IPOs to achieve high premiums and highlighting the importance of float considerations in new listings.
IPOX® CEO Josef Schuster told Bloomberg that Venture Global's IPO valuation cut "jolts" the market, signaling a crucial shift: investors now demand realistic valuations and rigorous IPO deal scrutiny, emphasizing increased investor discipline as the new norm.
IPOX® Research Analyst Dr. Lukas Muehlbauer, offered his perspective on the upcoming US IPO of Ascentage Pharma, a Chinese biopharmaceutical firm targeting a valuation of $1.75 billion. Ascentage, backed by Takeda Pharmaceutical, is seeking a US listing after its shares have already been trading on the Hong Kong stock exchange since 2019.
IPOX® CEO Josef Schuster shared his insights on the upcoming IPO of Smithfield Foods, which aims for a valuation of up to $10.73 billion. The pork producer's return to the U.S. stock market after over a decade is one of the first major consumer IPOs of the year, potentially setting a precedent for other companies in the sector.